TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07764627: A Phase II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG301 Injection in Patients With Antibody-Mediated Rejection (AMR) After Ren

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07764627 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07764627 Rescue Dossier →